Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

-License, collaboration, and other

6,4767,827Total revenue

23,00417,949Operating costs and expenses:Cost of goods sold

11,6618,707Research and development

45,61835,085General and administrative

11,12910,414Impairment of long-lived assets

-1,675Total operating costs and expenses

68,40855,881Loss from operations

(45,404)(37,932)Non-operating income (expense):Interest income 

314632Interest expense

(4,645)(2,548)Non-cash interest expense on liability related to sale of future royalties

(5,543)(1,785)Other income (expense), net

427660Total non-operating expense, net

(9,447)(3,041)Loss before provision for income taxes

(54,851)(40,973)Provision for income taxes

212124Net loss

$ (55,063)$ (41,097)Basic and diluted net loss per share

$
(0.48)$
(0.36)Weighted average shares used in computing basic and diluted net loss per share

115,309114,531 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Three Months Ended March 31,20132012Cash flows from operating activities:Net loss 

$(55,063)$ (41,097)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on liability related to sale of future royalties 

5,5431,785Non-cash royalty revenue related to sale of future royalties

(4,393)-Stock-based compensation 

4,2454,234Depreciation and amortization 

3,6283,510Impairment of long-lived assets 

-1,675Other non-cash transactions

139295Changes in operating assets and liabilities:Accounts receivable 

2,158(5,865)Inventory

(112)(1,452)Other assets 

3,8444,305Accounts payable 

1,355(1,290)Accrued compensation 

179(4,620)Accrued expenses 

(1,130)1,094Accrued clinical tri
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... BIRMINGHAM, Ala. , Aug. 27, 2015 ... Integrated Outpatient Pharmacy Provider (IOPP™) is expanding ... launch of a medication-focused transition of care ... program, named "RxCare Management," provides hospitals with ... improve hospital performance measures that have been ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this software allows businesses to track product movement from beginning to end. , Businesses ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... in order to ease the stress on the atmosphere, and lessen the number and ... the real cause of global warming and urges them to look into his studies ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... Enhanced design now features End-of-Life capability and longer ... LLC, a leading supplier of batteries for implantable ... enhanced Lithium Carbon Monofluoride (Li/CFx) battery technology with ... the market. The technology includes a proprietary new ...
... Remote Magnetic Navigation prominently featured on the HRS 2009 ... STXS ) said today that the Heart Rhythm ... in which its Niobe system is either featured or ... presentations include new efficacy data on the use of ...
... takes shared responsibility to a whole new level. ... saving $2 trillion in healthcare costs over the next ... is within our grasp.Blue Shield of California has long ... We are pleased that these groups are embracing the ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... Drug Information Association (DIA), the premiere neutral, global, multidisciplinary association ... the launch of its new online Career Center--a highly targeted ... ... Horsham, PA, USA (Vocus) May 11, 2009 -- The ...
... on Kidz-Med Thermofocus(R) 5-in-1WESTON, Fla., May 11 American ... revenue results for the first quarter ending March 31, ... with net sales of $263,603 for the first quarter ... for the first quarter of 2008.The sales increase was ...
Cached Medicine News:Health News:EaglePicher Medical Power Announces New Li/CFx Battery Technology 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: